These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 19602213)
1. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Oostenbrink JB; Al MJ; Oppe M; Rutten-van Mölken MP Value Health; 2008 Dec; 11(7):1070-80. PubMed ID: 19602213 [TBL] [Abstract][Full Text] [Related]
2. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096 [TBL] [Abstract][Full Text] [Related]
3. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM Value Health; 2005; 8(1):32-46. PubMed ID: 15841892 [TBL] [Abstract][Full Text] [Related]
4. Which long-acting bronchodilator is most cost-effective for the treatment of COPD? Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Oba Y Mayo Clin Proc; 2007 May; 82(5):575-82. PubMed ID: 17493425 [TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Hettle R; Wouters H; Ayres J; Gani R; Kelly S; Lion M; Decramer M Respir Med; 2012 Dec; 106(12):1722-33. PubMed ID: 23040833 [TBL] [Abstract][Full Text] [Related]
7. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease]. Schramm W; Haake D; Brandt A Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401 [TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844 [TBL] [Abstract][Full Text] [Related]
10. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Gani R; Griffin J; Kelly S; Rutten-van Mölken M Prim Care Respir J; 2010 Mar; 19(1):68-74. PubMed ID: 20094687 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217 [TBL] [Abstract][Full Text] [Related]
12. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system. Onukwugha E; Mullins CD; DeLisle S Value Health; 2008; 11(5):980-8. PubMed ID: 18194405 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Najafzadeh M; Marra CA; Sadatsafavi M; Aaron SD; Sullivan SD; Vandemheen KL; Jones PW; Fitzgerald JM Thorax; 2008 Nov; 63(11):962-7. PubMed ID: 18621985 [TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Price D; Gray A; Gale R; Asukai Y; Mungapen L; Lloyd A; Peters L; Neidhardt K; Gantner T Respir Med; 2011 Nov; 105(11):1635-47. PubMed ID: 21764277 [TBL] [Abstract][Full Text] [Related]
15. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Lee KH; Phua J; Lim TK Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566 [TBL] [Abstract][Full Text] [Related]
16. Methods to analyse cost data of patients who withdraw in a clinical trial setting. Oostenbrink JB; Al MJ; Rutten-van Mölken MP Pharmacoeconomics; 2003; 21(15):1103-12. PubMed ID: 14596629 [TBL] [Abstract][Full Text] [Related]
17. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Siebert U; Rochau U; Claxton K Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327 [TBL] [Abstract][Full Text] [Related]
18. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734 [TBL] [Abstract][Full Text] [Related]
19. Value of information analysis in telehealth for chronic heart failure management. Grustam AS; Buyukkaramikli N; Koymans R; Vrijhoef HJM; Severens JL PLoS One; 2019; 14(6):e0218083. PubMed ID: 31220101 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Oba Y Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]